Trending Now
Latest News
AstraZeneca looks to salvage data from negative Imfinzi lung cancer study
British drugmaker AstraZeneca is doing a deep dive into data from an immunotherapy study in lung cancer whose negative results were announced last month...
Memorial Sloan Kettering selects MyHealthDirect solution for patient self-scheduling
In an effort to enable online patient self-scheduling, Memorial Sloan Kettering Cancer Center has deployed a solution from MyHealthDirect, a Nashville, Tennessee-based company that...
More
AstraZeneca looks to salvage data from negative Imfinzi lung cancer study
British drugmaker AstraZeneca is doing a deep dive into data from an immunotherapy study in lung cancer whose negative results were announced last month...
Memorial Sloan Kettering selects MyHealthDirect solution for patient self-scheduling
In an effort to enable online patient self-scheduling, Memorial Sloan Kettering Cancer Center has deployed a solution from MyHealthDirect, a Nashville, Tennessee-based company that...
CVS and Sharecare team up to help the underinsured afford meds
Atlanta, Georgia-based digital health company Sharecare has inked a deal with CVS Caremark – the PBM arm of the pharmacy chain – to launch...
FDA Approves Udenyca (pegfilgrastim-cbqv), a Biosimilar to Neulasta
FDA Approves Udenyca (pegfilgrastim-cbqv), a Biosimilar to Neulasta
REDWOOD CITY, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ: CHRS), today announced that...
FDA Approves Empliciti (elotuzumab) Plus Pomalidomide and Dexamethasone, a New Immunotherapy Combination for Certain...
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Empliciti (elotuzumab) injection for intravenous use...
